Clinical trial
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of…
NCT00358176 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00358176 |
|---|---|
| Title | Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women |
| Official title | A Multicenter, Double-blind, Randomized, Active-controlled, Parallel Group, Noninferiority Study Comparing 75mg Risedronate Dosed on 2 Consecutive Days Monthly With 5mg Daily Risedronate in the Treatment of Postmenopausal Osteoporosis as Assessed Over 24 Months. |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Procter and Gamble Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis Postmenopausal |
| Intervention type | Drug |
| Interventions | Risedronate (HMR4003) |
| Enrollment | 1,231 |
| Start date | Jul 1, 2004 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Jul 31, 2006 |
| Last update posted | Dec 15, 2009 |
| Countries | Argentina, Australia, Canada, Czechia, France, Lebanon, Poland, South Africa, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: